What's hold­ing back biotech M&A? SVB tracks a trend and calls a come­back

The deal­mak­ers in bio­phar­ma have had some ex­tra time on their hands in the first half of 2017. M&A has slowed con­sid­er­ably, but one promi­nent play­er in the field is keep­ing the faith that H2 will make up for the lag.

Sil­i­con Val­ley Bank has put out its re­port on the first half of the year, and you can see from the chart be­low — which com­bines biotech IPOs and M&A — what I mean by a slow­down.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.